The Value Signal — October 23, 2026

746 articles scanned · 15 high-signal

Signal Map

Executive Summary

Washington is moving on every major Medicare cost lever at once, from risk adjustment and drug pricing to utilization management, just as Medicare Advantage becomes the program's majority pathway.

On HCC / Risk Scoring, JAMA presents a congressional view on reforming Medicare Advantage risk adjustment, signaling that coding intensity is a legislative target and not merely a regulatory one. The stakes are structural: Healthcare IT News reports that more than half of Medicare beneficiaries are now enrolled in Advantage plans. Medicare rulemaking is already in motion. According to Wakely, CMS has released part of its proposed 2028 policy and technical rule, which implements reconciliation-bill provisions including Part D compensation changes and MA provider directory changes. On Drug Pricing / Negotiation, Health Affairs reports that the administration has finalized the Medicare Part B International Reference Pricing Model. Meanwhile, Pharmaceutical Commerce details a 340B rebate pilot standoff involving the courts, Congress and drugmakers.

Prior Authorization remains the sharpest friction point. Becker's ASC cites a report finding that CMS' WISeR program left patients waiting months for care, while MedCity News reports that Amazon, Google and other major employers are backing the CMS prior authorization effort. In Medicaid, conditions are improving for payers. Healthcare Dive reports that states raised Medicaid rates in July, and Elevance now expects its Medicaid margin to beat its prior forecast of -1.75%. On Value-based Care, ACHE calls for rethinking the payer-provider relationship itself. In Home-based Care, Home Health Care News reports that HHS has launched a kidney care plan to expand home dialysis and spur competition, extending value-based logic into the home.